Skip to main navigation

Overview
Events & Presentations
News Releases
- For Global Media Only
- For U.S. Media Only
Corporate Governance
Stock
Financial & Filings

News Releases
Intended for U.S. Media Only

News Releases

Year

September 23, 2023

Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency

September 15, 2023

Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

September 14, 2023

Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism

September 5, 2023

Ascendis Pharma Reports Second Quarter 2023 Financial Results

September 5, 2023

New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism

September 5, 2023

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

August 24, 2023

Ascendis Pharma A/S Announces Three Upcoming Investor Presentations

August 15, 2023

Ascendis Pharma to Report Second Quarter 2023 Financial Results and Provide Business Update on September 5, 2023

June 17, 2023

One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

June 13, 2023

Ascendis Pharma Showcases Its Latest Endocrinology Programs, Data, and Research at ENDO 2023

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 27

Shareholder Tools

RSS Feeds

Email Alerts

IR Contact

Footer Corporate Menu

TransCon
About us
Pipeline
Patients
Investors & News
Contact Us

Footer Copyrights Menu

Privacy Policy
Terms of Use

Ascendis, Ascendis Pharma, Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group

© September 2023 Ascendis Pharma